Evidence map›Paper›PMID 40896699›Full record

ArticleIranian journal of basic medical sciences2025

Induction of the STING-dependent DNA damage pathway by cucurbitacin B enhances immunotherapy efficacy in osteosarcoma.

Bin Luo, Qing Lu, Qiang Wang, Yingchao Shen, Yiming Miao, Yong Ma

Abstract read
In one paragraph

Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bin LuoDepartment of Orthopaedics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu 215500, China.
Qing LuDepartment of Orthopaedics, The Third People's Hospital of Xiangcheng District, Suzhou 215100, China.
Qiang WangDepartment of Orthopaedics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu 215500, China.
Yingchao ShenDepartment of Orthopaedics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu 215500, China.
Yiming MiaoDepartment of Orthopaedics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu 215500, China.
Yong MaInstitute of Traumatology & Orthopedics and Laboratory of New Techniques of Restoration & Reconstruction of Orthopedics and Traumatology.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Osteosarcoma (OS) is a highly aggressive bone tumor with limited therapeutic options. Cucurbitacin B (CuB), a natural compound derived from Cucurbitaceae plants, has demonstrated antitumor activity in various malignancies; however, its mechanisms in OS remain unclear. This study aims to elucidate the antitumor effects of CuB in OS and explore its molecular mechanisms. Materials and Methods: MG63 and K7M2 OS cells were treated with CuB, and cell viability was assessed using the cell counting kit-8 (CCK8) assay. Colony formation assays were employed to evaluate proliferation, while flow cytometry was used to analyze apoptosis and cell cycle distribution. DNA damage was determined by immunofluorescence staining and comet assay. Western blotting was used to detect proteins involved in activating the stimulator of the interferon genes (STING) pathway. Results: CuB inhibited OS cell proliferation, induced apoptosis, and caused G2/M cell cycle arrest. It activated the STING pathway and induced DNA damage. Conclusion: CuB exerts anti-OS effects by inducing DNA damage, activating the STING pathway, enhancing immune responses, and synergizing with anti-PD-L1, highlighting its therapeutic potential.

Indexed as

cGAS-STING pathwayCucurbitacin BDNA damageOsteosarcomaPD-L1

Identifiers

PMID40896699
PMCPMC12399069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.